An observational study in Myotonic Dystrophy, sponsored by Newcastle University. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Newcastle University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Myotonic Dystrophy with a site in United Kingdom — 12 open to participants now, 14 under way, 5 of them phase 3. Myotonic Dystrophy · United Kingdom.
Among the 22 studies in Myotonic Dystrophy with a site in United Kingdom, this one is the only one that started in 2013, is one of 5 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 6th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →12 of the 22 studies in Myotonic Dystrophy with a site in United Kingdom are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in United Kingdom, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Dyne Therapeutics · Sites in United Kingdom, United States, Australia and 9 more countries
Ages 16+
Sanofi · Sites in United Kingdom, United States, Argentina and 3 more countries
Ages 10–55
Lupin Ltd. · Sites in United Kingdom, Belgium, Denmark and 3 more countries
Ages 16+
PepGen Inc · Sites in United Kingdom, Canada, New Zealand and 1 more country
Ages 16–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 7
First in 2013; this study’s year is marked. 1 started in 2013.
This study's planned enrollment of 900 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Median enrollment 70 across the 17 interventional studies, 213 across the 5 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 10 most frequent:
Newcastle University is the lead sponsor of 60 studies on the registry; 15 are open to participants now.
Newcastle University has 1 study filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
6 of the studies in Myotonic Dystrophy with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523400Phase 3Lupin Ltd.The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | 2027-06 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06667453PepGen IncA Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies in Myotonic Dystrophy with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myotonic dystrophy (dystrophia myotonica - DM) exists in two forms, usually referred to as DM1 (type 1) and DM2 (type 2). Both conditions are genetic disorders but each affects a different gene. DM1 is the most common adult-onset muscular dystrophy, and is thought to affect at least 1 in 8,000 people worldwide.
The aim is to facilitate a questionnaire based research study in order to better characterise and understand the disease in the UK. By maintaining a national registry this will help identify potential participants eligible for clinical trials in the future.
The UK DM Patient Registry (https://www.dm-registry.org/uk/) aims to recruit any individual, from anywhere within the United Kingdom, with a diagnosis of myotonic dystrophy. Participants may be referred to the registry by health care professionals, or genetic testing/laboratory centres who are aware of the registry. Alternatively, a participant may have discovered the registry via promotional activities or by their own online searches. After completing the consent process, participants are able to enter information on to the registry platform (note all forms are also available offline as well). This is an ongoing database and all participants will invited to update their information on an annual basis.
The registry is sponsored by Muscular Dystrophy UK, Cure-DM and the Myotonic Dystrophy Support Group.
The database is divided into two main sections:
The database is designed to be self reporting, however where specialised clinical or genetic information is required, the neuromuscular specialist in charge of the participants care can be invited to provide some additional information. The participant is able to select a health care provider from a pre-populated list at registration stage, if they wish to (optional feature). This information is included in the patient information and consent.
Participants with Myotonic Dystrophy will volunteer to participate in this study. The study will be advertised through neuromuscular disease clinics, the registry website, patient organisations and conferences and meetings throughout the UK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Patient Registry
Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Patient questionnaire
Patient reported myotonic dystrophy clinical diagnosis, symptoms relating to muscle weakness, motor function, medication use, family history and ethnicity.
Time frame: 12 months
Clinician questionnaire
Clinician reported patient cardiac measures, medication use, respiratory measures and genetic confirmation of myotonic dystrophy.
Time frame: 12 months
Started May 2013 (actual). Primary completion is estimated for Jan 2030, 200 months after the start.
Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 200 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Newcastle University